drugset / Trial / NCT03500848
Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation
Phase 2/3
Unknown
130 enrolled
Southern Medical University, China
First Affiliated Hospital, Sun Yat-Sen University · collabNanfang Hospital, Southern Medical University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, randomized, controlled clinical trial, in order to compare sirolimus-based (tacrolimus-free) versus tacrolimus-based (sirolimus-free) immunosuppression regimen for Hepatocellular Carcinoma (HCC) patients after liver transplantation.
Timeline
- Start
- 2018-05-01
- Primary completion
- 2023-05-31
- Completion
- 2023-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | 2 mg | — |
| Comparator | Tacrolimus | Small molecule | 1 mg | — |
| Background | MMF | Unknown | — | — |
Indications
No indication recorded.